Clinical trials
Diabetes (Insulin-requiring, Type 1 or Type 2) clinical trials
Below are recruiting diabetes (insulin-requiring, type 1 or type 2) clinical trials, each written for real people, not researchers. We’re tracking 2,191 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05177133RecruitingPhase 2
First-line treatment for MSI-high stomach or esophagus cancer
This Phase 2 trial tests whether adding an anti–PD-1 immunotherapy (retifanlimab) and chemotherapy (capecitabine plus oxaliplatin, with leucovorin) works better for people with metastatic or inoperable stomach or gastroesophageal junction cancer that has defective mismatch repair (dMMR). If you’re eligible, it may help shrink tumors and slow the disease without needing prior chemotherapy for metastatic cancer.
AmsterdamAges 18 years+ - NCT05521984RecruitingPhase 1
Dapagliflozin trial for children with hard-to-treat brain tumors
This Phase 1 trial tests whether dapagliflozin (an SGLT2 medicine) can help shrink or control certain pediatric brain tumors or other solid tumors that have come back or won’t respond. It’s designed mainly to check safety and early signs of effect in children and young adults who have limited treatment options.
St Louis, MissouriAges 6–21 - NCT06885385RecruitingPhase 2
Study of JS207 with or without JS015 and chemo for colorectal cancer
This trial tests a new drug combination (JS207 with or without JS015) along with chemotherapy for people with advanced colorectal cancer that has not spread to other parts of the body. It aims to see if the treatment is safe and helps shrink tumors.
Beijing, Beijing MunicipalityAges 18–75 - NCT07530809Recruiting
Time-Restricted Eating for Fatty Liver Disease
This study tests whether eating within a limited time window each day can improve fatty liver disease (a buildup of fat in the liver). If you have moderate-to-advanced fatty liver disease and are overweight, this trial might help you learn if changing when you eat—rather than what you eat—can reduce liver fat and improve your health.
Homburg, SaarlandAges 18–75 - NCT04267848RecruitingPhase 3
Testing immunotherapy with chemo after lung cancer surgery
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
Anchorage, AlaskaAges 18 years+ - NCT05697861Enrolling by invitation
Follow-up study for people previously treated with NTLA-2001
This study checks how people are doing long-term after receiving NTLA-2001 in an Intellia clinical trial. If you previously took part and agree to be followed, this may help the researchers understand lasting safety and effects.
ParisAges 18 years+ - NCT06662786RecruitingPhase 3
Amivantamab plus chemo vs. standard chemo for left-sided colorectal cancer
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
Gilbert, ArizonaAges 18 years+ - NCT07533942RecruitingPhase 2
Testing JZP3507 for Recurrent Grade 2 or 3 Brain Tumors
This study tests a new drug called JZP3507 for people with meningioma (a type of brain tumor, grades 2 or 3) that has come back or grown despite previous treatment. The goal is to see if this medication can slow or shrink the tumor.
San Francisco, CaliforniaAges 18 years+ - NCT03911388RecruitingPhase 1
HSV G207 for Children with Recurrent Cerebellar Brain Tumors
This trial is testing a virus called HSV G207, which is injected directly into the tumor, to treat children and young adults with a type of brain tumor in the cerebellum that has come back or not responded to standard treatments.
Birmingham, AlabamaAges 3–22 - NCT07140614RecruitingPhase 1
Study of EDK060 for adults with CMT1A
This trial tests a new medicine called EDK060 for people with Charcot-Marie-Tooth disease type 1A (CMT1A). The study will check if the drug is safe and how the body processes it, with the goal of finding better treatments for this condition.
Ottawa, OntarioAges 18–60 - NCT04371445RecruitingPhase 4
Dextenza drops after eye surgery to reduce post-op pain
This trial studies whether Dextenza (a steroid pain-relief eye insert) can improve comfort after a specific type of retina surgery (pars plana vitrectomy). It looks at people getting surgery for conditions like macular hole, epiretinal membrane, or vitreomacular traction.
Cleveland, OhioAges 18 years+ - NCT06427941RecruitingPhase 1
Study of BGB-B2033 drug for advanced solid tumors
This trial tests a new drug, BGB-B2033, alone or with other treatments, for people with advanced liver, stomach, lung, or germ cell cancers that have not responded to standard therapy. The goal is to see if the drug is safe and works against these tumors.
Goodyear, ArizonaAges 18 years+ - NCT07216235RecruitingPhase 3
Long-term study of saroglitazar for PBC with cirrhosis
This study tests a new drug called saroglitazar to see if it can improve long-term outcomes in people with primary biliary cholangitis (PBC) who have cirrhosis. It may be an option if you are already on UDCA or cannot take it, and if your liver function tests meet certain levels.
Marietta, GeorgiaAges 18 years+ - NCT07497880RecruitingPhase 2
Study of a new pill for weight loss in adults with obesity
This trial tests a daily pill called KAI-7535 to see if it helps people with obesity or overweight lose weight safely. It is for adults who have a body mass index (BMI) of 27 or higher and at least one weight-related health problem, such as high blood pressure or type 2 diabetes.
Chandler, ArizonaAges 18–75 - NCT07111273Recruiting
Predicting relapse in ulcerative colitis with early stool tests
This study looks at whether early stool tests (fecal immunochemical test and calprotectin) can predict when ulcerative colitis symptoms might return. It is for people who have never taken biologic medications.
Jinan, ShandongAges 18–75 - NCT06825559RecruitingPhase 1
Saroglitazar safety in moderate liver impairment from cholestatic disease
This trial tests how the body processes saroglitazar in people with moderate liver impairment caused by cholestatic liver disease. The goal is to ensure the drug is safe and dosed correctly for this group.
Indianapolis, IndianaAges 18–80 - NCT05552157RecruitingPhase 2/Phase 3
Study of treatments for early onset Alzheimer's caused by genetic mutations
This trial tests potential treatments for people who are at risk for or have early onset Alzheimer's disease due to a specific genetic mutation. It aims to find treatments that could slow or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT06647498RecruitingPhase 2/Phase 3
Study of a treatment for early-onset Alzheimer's caused by a gene change
This study tests a potential disease-modifying treatment for people who have a specific gene mutation that causes early-onset Alzheimer's disease. The goal is to see if the treatment can delay or prevent symptoms.
Birmingham, AlabamaAges 18 years+ - NCT06563505RecruitingPhase 2
Study of mosunetuzumab plus zanubrutinib for relapsed marginal zone lymphoma
This trial tests a combination of two drugs (mosunetuzumab and zanubrutinib) for people with marginal zone lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help control the lymphoma.
Houston, TexasAges 18 years+ - NCT07724223RecruitingPhase 2
Combination targeted therapy for advanced colorectal cancer
This trial tests a combination of two targeted drugs (fruquintinib and a drug that targets EGFR) as a third-line treatment for people with a specific type of colorectal cancer that has not responded to previous therapies. It may offer a new option for patients whose tumors are 'wild-type' for certain genes.
Beijing, Beijing MunicipalityAges 18–75 - NCT05561595Recruiting
Reducing health-related stigma through group support
This trial tests a virtual group program to help people cope with health-related stigma from conditions like obesity, cancer, HIV, diabetes, skin disease, or chronic pain. It aims to reduce internalized stigma and improve well-being.
Gainesville, FloridaAges 18 years+ - NCT05951816RecruitingPhase 1
Imaging study for amyloidosis in heart and body
This study tests a new imaging agent (99mTc-p5+14) that helps doctors see amyloid deposits in the body, especially in the heart. It is for healthy volunteers and people with AL or ATTR amyloidosis that has affected the heart.
Knoxville, TennesseeAges 18 years+ - NCT06929273RecruitingPhase 3
Long-term safety study of KarXT for bipolar I mania
This study tests the long-term safety of KarXT for people with bipolar I disorder who are having a manic or mixed episode. It is for people who either completed a previous KarXT study or are new to the study and have moderate to severe mania symptoms.
Glendale, ArizonaAges 18–65 - NCT07284979RecruitingPhase 3
Weekly injection for obesity without diabetes
This trial tests a new once-weekly injection called Ribupatide for weight loss in people with obesity who do not have diabetes. It compares the study drug to an existing medication (semaglutide) and a placebo to see how well it works and if it's safe.
Glendale, ArizonaAges 18 years+
Hear when a new Diabetes (Insulin-requiring, Type 1 or Type 2) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for diabetes (insulin-requiring, type 1 or type 2)?
- Yes. Clin2 currently lists 2,191 recruiting diabetes (insulin-requiring, type 1 or type 2) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a diabetes (insulin-requiring, type 1 or type 2) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a diabetes (insulin-requiring, type 1 or type 2) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.